Valo Health experts discuss how technology, data, and biology are converging to redefine how drug discovery and development are done
CSO Karin Conde-Knape and Chief Causal AI Officer Chris Anagnostopoulos discuss the difference between data collection in clinical trials and clinical care, and why they believe our industry has been underutilizing and sometimes misusing these data sets. They discusses the latest ways of harnessing technology to find targets that have a higher probability of clinical success.
The Experts
Karin Conde‑Knape, PhD is Senior Vice President and Chief Scientific Officer at Valo Health, where she leads scientific strategy and execution across the company, advancing a diverse portfolio of internal programs and global collaborations aimed at delivering transformative therapies for patients. She brings more than two decades of experience across multiple disease areas within global pharmaceutical organizations.
Prior to joining Valo Health, Dr. Conde‑Knape had an extensive career at Novo Nordisk, where she held multiple senior leadership roles, including Senior Vice President of Early Development and Global Drug Discovery. In this capacity, she led research and early development across multiple therapeutic areas and modalities, driving innovation through both internal teams and external collaborations.
Before Novo Nordisk, Dr. Conde‑Knape served as Vice President, Cardiovascular and Metabolism at Johnson & Johnson, where she was responsible for identifying, establishing, and managing external scientific partnerships spanning early research through clinical proof of concept in cardiovascular and metabolic diseases. Earlier in her career, she held senior research leadership roles at Roche, including Global Head of Discovery within the Cardiovascular, Renal, and Metabolism Disease Therapeutic Area.
Dr. Conde‑Knape has been recognized as one of the “Fiercest Women in Life Sciences” by Fierce Pharma and one of the top 20 women breaking new ground in biopharma R&D by Endpoints News. She holds a PhD in Nutritional Biochemistry from the University of Connecticut and has authored numerous publications in cardiometabolic disease biology and translational research.
Chris Anagnostopoulos, PhD serves as Chief Causal AI Officer at Valo, where he leads the development and application of causal AI to advance drug discovery. He brings a rare, interdisciplinary background spanning statistics, artificial intelligence, life sciences, and the technology sector.
Chris was a tech fellow Partner at QuantumBlack, AI by McKinsey, where he served as director of life sciences innovation, pushing the frontier of AI, causal inference and ML to advance drug discovery and development. Earlier in his career, he was Founder and CEO of an AI consultancy and Director of R&D at a London‑based technology company where he led teams building next‑generation programming languages for AI.
Chris received an undergraduate degree in Mathematics from the University of Cambridge, an MSc in Artificial Intelligence from the University of Edinburgh, and a PhD in Statistical Machine Learning from Imperial College London. He held a prestigious research fellowship at the Statistical Laboratory at the University of Cambridge before becoming a tenured member of faculty at Imperial College London, where he continues to hold an honorary Associate Professorship. He is a Chartered Statistician (C.Stat) of the Royal Statistical Society and has authored multiple technical publications in leading peer‑reviewed journals.
.png){kind=logo}